Clinical Trials Browser

Phase 2 × IT-101 × Clear all

NCT03531827 2022-07-12

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Phase 2 Terminated

4 enrolled 12 charts

Prostatic Neoplasms

NCT01803269 2020-06-26

Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer

Phase 2 Terminated

29 enrolled 14 charts

Small Cell Lung Carcinoma

NCT01380769 2020-05-28

A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

157 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT01652079 2018-07-02

CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer

Phase 2 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01612546 2018-02-01

Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery

Phase 2 Completed

10 enrolled 6 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Stomach Neoplasms